| Category | Key points | Key sources |
|---|---|---|
| Identity/family | ADRB2 encodes the human β2-adrenergic receptor (β2AR), a class A/rhodopsin-like 7-transmembrane G protein-coupled receptor activated by catecholamines; it is one of three β-adrenergic receptor isoforms and is widely expressed across tissues. | (pqac-00000006, pqac-00000010, pqac-00000016) |
| Localization | β2AR functions primarily at the plasma membrane; in cardiomyocytes it is enriched in the T-tubular network. After activation it internalizes to early endosomes, where signaling can continue, and adrenergic receptors can also signal from intracellular compartments in some contexts. | (pqac-00000012, pqac-00000013, pqac-00000015) |
| Endogenous ligands | The principal endogenous agonists are epinephrine and norepinephrine/catecholamines. Synthetic agonists used experimentally or clinically include isoproterenol, salbutamol, fenoterol, and formoterol. | (pqac-00000003, pqac-00000007, pqac-00000009) |
| Canonical signaling | Canonically, β2AR couples to Gs, activating adenylyl cyclase, increasing cAMP, and activating PKA. In airway smooth muscle this lowers intracellular Ca2+ and promotes bronchodilation; cAMP also supports mucociliary clearance and related airway functions. | (pqac-00000006, pqac-00000016, pqac-00000017) |
| Noncanonical/endosomal signaling | β2AR can also signal through β-arrestin-dependent pathways and, in some contexts, switch from Gs to Gi after phosphorylation. Endosomal GPCR signaling models show receptors can sustain G-protein signaling after internalization, including via receptor-G protein-β-arrestin “megaplex” assemblies. | (pqac-00000011, pqac-00000012, pqac-00000014, pqac-00000015) |
| Regulation/desensitization | Activated β2AR is phosphorylated by GRKs and PKA, recruiting β-arrestins that sterically uncouple G proteins, drive clathrin-mediated internalization, and sort receptors for recycling or degradation. β-arrestin scaffolds also link β2AR to ERK, p38 MAPK, NF-κB, Src, PI3K, and EGFR-transactivation pathways. | (pqac-00000006, pqac-00000011, pqac-00000012, pqac-00000013, pqac-00000017) |
| Key physiological roles | Established functions include bronchodilation, regulation of airway tone, mucociliary clearance, and anti-inflammatory effects in respiratory tissues. Additional roles include metabolic regulation (lipolysis, thermogenesis, glucose uptake) and cardioprotective/survival signaling via Gi/PI3K/AKT in some settings. | (pqac-00000003, pqac-00000006, pqac-00000007, pqac-00000013) |
| Clinical drug classes & examples | ADRB2 is the target of short- and long-acting β2-agonists used for asthma and COPD; examples include salbutamol/albuterol and formoterol. β-blockade of β2AR also contributes to nonselective β-blocker pharmacology in cardiovascular and portal-hypertension settings. | (pqac-00000003, pqac-00000004, pqac-00000017, pqac-00000000) |
| Pharmacogenomic variants & recent associations/statistics | Common coding variants include rs1042713 (Arg16Gly) and rs1042714 (Gln27Glu), with Thr164Ile as a rarer functional variant discussed in recent literature. A 2024 asthma study found rs1042714 associated with ΔFEV1 (p=0.023), FVC (p=0.012), % reversibility (p=0.012), and bronchodilator response (p=0.040); CC genotype showed lower ΔFEV1 4.9±4.8, ΔFVC 2.6±4.8, % reversibility 8.3±9.2, and 38.7% negative BDR. A 2025 COPD pharmacogenetics review concluded evidence for Arg16Gly/Gln27Glu effects on LABA response is mixed and not yet clinically actionable. | (pqac-00000008, pqac-00000004, pqac-00000005) |


*Table: This table summarizes the core functional annotation of human ADRB2/β2AR, covering identity, localization, signaling, regulation, physiological roles, therapeutics, and key pharmacogenomic findings. It is useful as a compact evidence map for gene/protein function grounded in the cited context sources.*